ADMA Biologics (ADMA) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.…

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.…

ADMA Biologics gains 20.9% after strong Q3 results, as surging Asceniv sales and a raised 2026 profit outlook offset Bivigam weakness and competitive pressures.…

After reaching an important support level, Adma Biologics (ADMA) could be a good stock pick from a technical perspective. ADMA surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend.…

From a technical perspective, Adma Biologics (ADMA) is looking like an interesting pick, as it just reached a key level of support. ADMA recently overtook the 200-day moving average, and this suggests a long-term bullish…

ADMA Biologics, Inc. (ADMA) Q3 2026 Earnings Call Transcript…

Adma Biologics (ADMA) came out with quarterly earnings of $0.22 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.16 per share a year ago.…

ADMA Biologics NASDAQ: ADMA raised its minimum full-year earnings expectations after third-quarter profit rose on stronger sales of ASCENIV and improved manufacturing yields, even as competitive pressure weighed on its B…

3Q 2026 Total Revenue of $141.1 Million, Increasing 5% Year-over-Year 3Q 2026 ASCENIV Revenue of $124.7 Million, Increasing 31% Year-over-Year 3Q 2026 GAAP Net Income of $49.9 Million, Increasing 37% Year-over-Year 3Q 2…

In the closing of the recent trading day, Adma Biologics (ADMA) stood at $11.41, denoting a -2.89% move from the preceding trading day.…

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's …

Adma Biologics (ADMA) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.…

RAMSEY, N.J. and BOCA RATON, Fla.…

Adma Biologics (ADMA) closed the most recent trading day at $11.24, moving +1.49% from the previous trading session.…

Optimized Process Demonstrated Effective Removal of Procoagulant Impurities While Maintaining Immunoglobulin Quality and Increasing IgG Yield…

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) ana…

Myriad Genetics (NASDAQ: MYGN - Get Free Report) and ADMA Biologics (NASDAQ: ADMA - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses based on the streng…

In the latest trading session, Adma Biologics (ADMA) closed at $10.33, marking a +1.87% move from the previous day.…

Recently, Zacks.com users have been paying close attention to Adma Biologics (ADMA). This makes it worthwhile to examine what the stock has in store.…

Shares of ADMA Biologics Inc (NASDAQ: ADMA - Get Free Report) have been assigned an average rating of "Moderate Buy" from the six research firms that are covering the stock, Marketbeat.com reports. Three investment analy…

In the most recent trading session, Adma Biologics (ADMA) closed at $10, indicating a -1.24% shift from the previous trading day.…

Adma Biologics (ADMA) closed at $9.52 in the latest trading session, marking a -1.86% move from the prior day.…

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) ana…

Adma Biologics (ADMA) closed the most recent trading day at $9.13, moving +2.01% from the previous trading session.…

Philadelphia, Pennsylvania--(Newsfile Corp. - September 14, 2026) - National plaintiffs' law firm Berger Montague PC announces an investigation into potential breaches of fiduciary duty by the Board of Directors of ADMA …

PHILADELPHIA, Sept. 8, 2026 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces an investigation into potential breaches of fiduciary duty by the Board of Directors of ADMA Biologics, Inc. (NASDAQ:…

PHILADELPHIA, Aug. 31, 2026 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces an investigation into potential breaches of fiduciary duty by the Board of Directors of ADMA Biologics, Inc. (NASDAQ:…

New York, New York--(Newsfile Corp. - August 26, 2026) - Bernstein Liebhard LLP, a nationally recognized investor rights law firm, announces that it is investigating potential breaches of fiduciary duty by certain direct…

Philadelphia, Pennsylvania--(Newsfile Corp. - August 24, 2026) - National plaintiffs' law firm Berger Montague PC announces an investigation into potential breaches of fiduciary duty by the Board of Directors of ADMA Bio…

LOS ANGELES, Aug. 21, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against ADMA Biologics, Inc. ("ADMA" or "the Company") (NASDAQ: ADMA) for violations of §§10(b) and 20(a) of the Se…

LOS ANGELES, Aug. 21, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ADMA Biologics, Inc. ("ADMA" or "the Com…
Kept in their own lane. A press release is the company talking, not reporting.
No upcoming events in the feeds.

